首页> 外文期刊>Sub-cellular biochemistry >Design of Novel Vaccines Based on Virus-Like Particles or Chimeric Virions
【24h】

Design of Novel Vaccines Based on Virus-Like Particles or Chimeric Virions

机译:基于病毒样颗粒或嵌合病毒粒子的新型疫苗设计

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Virus-like particles (VLPs) are formed by viral structural proteins that, when overexpressed, spontaneously self-assemble into particles that are antigenically indistinguishable from infectious virus or subviral particles. VLPs are appealing as vaccine candidates because their inherent properties (i.e., virus-sized, multimeric antigens, highly organised and repetitive structure, not infectious) are suitable for the induction of safe and efficient humoral and cellular immune responses. VLP-based vaccines have already been licensed for human and veterinary use, and many more vaccine candidates are currently in late stages of evaluation. Moreover, the development of VLPs as platforms for foreign antigen display has further broadened their potential applicability both as prophylactic and therapeutic vaccines. This chapter provides an overview on the design and use of VLPs for the development of new generation vaccines.
机译:病毒样颗粒(VLP)由病毒结构蛋白形成,当过表达时,自发地自组装成抗原来自传染性病毒或亚类亚病毒颗粒的粒子。 VLPS作为疫苗候选者吸引,因为它们的固有性质(即病毒尺寸,多聚体抗原,高度有组织和重复结构,而不是传染性)适用于诱导安全有效的体液和细胞免疫应答。 基于VLP的疫苗已经为人类和兽医使用许可,并且许多疫苗候选人目前正在评估的晚期阶段。 此外,VLPS作为外来抗原显示器的平台的发展进一步扩展了它们作为预防性和治疗疫苗的潜在适用性。 本章概述了VLPS开发新一代疫苗的设计和使用概述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号